Pharmaceuticals News and Research

RSS

BioNeutral third quarter revenue increases to $15,500

BioNeutral Group Inc., a specialty chemical technology-based life science company, today announced financial results for the third quarter and nine-month period ended July 31, 2010.

21 Sep 2010

Dengue fever vaccine in the pipeline

Australians researchers are moving towards producing the first ever vaccine for dengue fever, the potentially life-threatening infection spread by mosquitoes in the tropics. At present late stage clinical trials are underway for a vaccine that would protect against all four known strains of the disease. Participants are now being recruited in Perth, Adelaide and Brisbane.

20 Sep 2010

ICF International awarded re-compete contract to provide IT, scientific support services to NCTR

ICF International, a leading provider of consulting services and technology solutions to government and commercial clients, has been awarded a $31.8 million re-compete contract by the U.S. Food and Drug Administration to provide information technology and scientific support services to the National Center for Toxicological Research.

20 Sep 2010

PAREXEL and Eli Lilly enter strategic functional service provider relationship

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the establishment of a strategic functional service provider relationship with Eli Lilly and Company, a global pharmaceutical company, to support study start-up and site monitoring of clinical trials throughout the Asia/Pacific region. PAREXEL will assist Lilly in bringing greater efficiencies to its clinical research studies to help meet Lilly's development and commercialization goals.

From Parexel 20 Sep 2010

Lisofylline drug effective for Type 2 diabetes

Australian scientists, in association with US pharmaceutical company DiaKine Therapeutics, have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes.

20 Sep 2010

Cellectis bioresearch, Helix Biocon collaborate to promote cGPS service in India

Cellectis bioresearch, the specialist in genome customization and subsidiary of Cellectis and Helix BioService & Consultants Pvt Ltd (Helix Biocon), today announced that they will join forces for the promotion of Cellectis bioresearch's meganuclease-based products and services in India.

20 Sep 2010

Medical technology paving the way

The annual Australian technology “Academy Awards” presentation marked a significant milestone for Sydney headquartered technology company Iris Interactive taking out three awards which sets them up for the world stage. Iris Interactive started 15 years ago by a working mother, Janaki Joshi, who identified a gap in the market for enterprise software focused on product commercialisation.

19 Sep 2010

Johnson & Johnson in talks to buy Crucell

Johnson & Johnson is in advanced negotiations to buy Dutch biotechnology company Crucell NV for €1.75 billion ($2.29 billion), the two companies said today. Giles Somers, senior healthcare analyst at Datamonitor comments:

19 Sep 2010

Murphy Analytics releases report on Bohai Pharmaceuticals

Bohai Pharmaceuticals Group, Inc., a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today announced the release of an in-depth initiation report by Patrick Murphy, CFA, principal of fee-based independent research firm Murphy Analytics.

18 Sep 2010

Diverse coalition urges California Governor to sign bill to provide health coverage for smoking cessation treatments

A large and unusually diverse of group of interests have come together to urge Governor Schwarzenegger to sign a key health related measure, Senate Bill 220 (Yee, D-San Francisco), which would provide health coverage of smoking cessation treatments and services.

18 Sep 2010

USC alumni gift $30 million to South Carolina College of Pharmacy

Two University of South Carolina alumni with a desire to transform pharmacy education and practice are making a $30 million gift to the university's South Carolina College of Pharmacy, the second-largest in the university's history.

18 Sep 2010

HRA Pharma, Watson enter licensing agreement for ulipristal acetate emergency contraceptive commercialization

HRA Pharma, a privately-held, European pharmaceutical company that develops healthcare solutions in reproductive health and endocrinology and makes them available worldwide, and Watson Pharmaceuticals, Inc. announced today that they have entered into a licensing agreement for the commercialization of HRA Pharma's next generation emergency contraceptive ulipristal acetate in Canada.

18 Sep 2010

Arizona State University and Quintiles sign new drug development deal

Arizona's contribution to the accelerated development of new, safe and effective medicines to help treat suffering patients in the US and around the world, will become greater following the signing of new deal between Arizona State University and Quintiles (www.quintiles.com), a global integrated biopharmaceutical services company which is a leader in managing clinical research.

18 Sep 2010

Ligand Pharmaceuticals transfers license rights to Proximagen for CXCR4 target

Ligand Pharmaceuticals Incorporated announced today that it has transferred exclusive license rights to Proximagen Limited for a series of compound hits related to the CXCR4 target with application for a number of indications including those related to the central nervous system. Ligand will receive an upfront payment and continue to be entitled to receive potential future milestone and royalty payments.

18 Sep 2010

CBO finds generic drugs save Medicare $33 billion in 2007

A new government report finds that the use of generic medications saved the Medicare program and its beneficiaries about $33 billion in 2007, The Associated Press/BusinessWeek report. The Congressional Budget Office report "says an additional $14 billion is expected as first-time generics enter the market through 2012. Medicare Part D is Medicare's prescription drug program" (9/15).

18 Sep 2010

Research Roundup: Assessing physician quality; Community health centers' future; Why doctors take gifts; Access to HIV treatment

Archives of Internal Medicine: Associations Between Physician Characteristics And Quality Of Care - Since "most patients do not have access to physician quality measures," they are often encouraged to use public information such as malpractice claims and board certification status to chose a doctor, according to this report that used 2004-2005 insurance claims from about 10,000 Massachusetts physicians for more than 1.13 million adults.

18 Sep 2010

FDA accepts to review Aricept NDA for Alzheimer's disease

Teikoku Pharma USA, Inc., an international specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for a new weekly transdermal patch of Aricept, a leading medication for the treatment of Alzheimer's disease.

18 Sep 2010

FDA reviews Actos drug for bladder cancer risk

The U.S. Food and Drug Administration today announced it has begun a safety review of the diabetes drug Actos (pioglitazone), after receiving preliminary results from a long-term observational study designed to evaluate the risk of bladder cancer associated with use of this drug.

18 Sep 2010

Elixir Medical commences enrollment in EXCELLA BD trial for DESyne BD Novolimus Eluting CSS

Elixir Medical Corporation, a developer of product platforms that combine innovative medical devices with potent pharmaceuticals for site-specific therapies, announced the initiation of patient enrollment in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir's next generation Novolimus Eluting Coronary Stent System (CSS) with bioabsorbable coating, the Elixir DESyne BD Novolimus Eluting CSS.

18 Sep 2010

Inspire Pharmaceuticals to present denufosol tetrasodium therapy data at ERS Annual Congress

Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the European Respiratory Society (ERS) Annual Congress September 18 - 22, 2010 in Barcelona, Spain.

17 Sep 2010